How to treat adverse reactions caused by sotoracib

Introduction: Sotorasib (LUMAKRAS) is a targeted drug used to treat patients with non-small cell lung cancer (NSCLC) carrying KRAS G12C mutations. Sotorasiib may cause adverse reactions, including diarrhea, musculoskeletal pain, nausea, fatigue, liver damage, and cough. Treatment of these adverse effects needs to be based on specific symptom presentation.

1. Diarrhea: It can be treated by adjusting diet, increasing water intake, and using antidiarrheal drugs.

2. Musculoskeletal pain: Nonsteroidal anti-inflammatory drugs (NSAIDs) or opioids may be needed to relieve pain.

3. Nausea and vomiting: Anti-nausea drugs, such as 5-hydroxytryptamine receptor antagonists, can be used, as well as diet and lifestyle adjustments.

4. Fatigue: Patients are advised to maintain adequate rest, moderate physical activity, and good nutritional status.

5. Liver damage: The patient's liver function needs to be monitored before and while taking sotoracib. If patients develop hepatic impairment, sotoraxib should be suspended, the dose reduced, or permanently discontinued.

6. Cough: You can use cough medicine to relieve symptoms.

7. Interstitial lung disease: If the patient develops symptoms of interstitial lung disease, sotoracib should be discontinued. If interstitial lung disease is diagnosed, sotoracib should be permanently discontinued.

8. QTc interval prolongation: For patients at risk of QTc interval prolongation, drugs that may further prolong the QTc interval should be avoided and electrocardiogram monitoring should be performed.

9. Drug-induced liver injury: Monitor liver laboratory tests before treatment and as clinically indicated during treatment. Reduce dose, suspend, or permanently discontinue sotoraxib based on severity.

10. Interstitial lung disease/non-infectious pneumonia: Monitor patients for new or worsening respiratory symptoms suggestive of ILD/pneumonitis. Discontinue sotorasib in patients with suspected ILD/non-infectious pneumonia or permanently if no other potential cause of ILD/non-infectious pneumonia is identified.

Precautions

Patients should closely monitor any adverse reactions while using sotoracib and inform their doctor immediately if symptoms occur. The doctor will adjust the treatment plan based on the patient's specific situation, which may include changing the dose, temporarily stopping the drug, or changing the treatment method. All treatments should be carried out under the guidance of a doctor to ensure patient safety and drug effectiveness.